FDA shoots down a biotech’s last-stand pa­tient pitch af­ter fault­ing da­ta

Stealth Bio­Ther­a­peu­tics ap­peared un­sure its pitch for an ul­tra-rare dis­ease would be ac­cept­ed when sub­mit­ting an NDA in Au­gust, and on Wednes­day its fears came …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER